These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37886555)

  • 1. MGMT promoter methylation in 1p19q-intact gliomas.
    Kinslow C; Siegelin MD; Iwamoto FM; Gallitto M; Neugut AI; Yu JB; Cheng SK; Wang TJC
    Res Sq; 2023 Oct; ():. PubMed ID: 37886555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MGMT promoter methylation in 1p19q-intact gliomas.
    Kinslow CJ; Siegelin MD; Iwamoto FM; Gallitto M; Neugut AI; Yu JB; Cheng SK; Wang TJC
    J Neurooncol; 2024 Jan; 166(1):73-78. PubMed ID: 38114801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.
    Kinslow CJ; Mercurio A; Kumar P; Rae AI; Siegelin MD; Grinband J; Taparra K; Upadhyayula PS; McKhann GM; Sisti MB; Bruce JN; Canoll PD; Iwamoto FM; Kachnic LA; Yu JB; Cheng SK; Wang TJC
    JAMA Oncol; 2023 Jul; 9(7):919-927. PubMed ID: 37200021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of
    Lam K; Eldred BSC; Kevan B; Pianka S; Eldred BA; Zapanta Rinonos S; Yong WH; Liau LM; Nghiemphu PL; Cloughesy TF; Green RM; Lai A
    Neurooncol Adv; 2022; 4(1):vdac030. PubMed ID: 35386566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
    Ostrom QT; Shoaf ML; Cioffi G; Waite K; Kruchko C; Wen PY; Brat DJ; Barnholtz-Sloan JS; Iorgulescu JB
    Neuro Oncol; 2023 Apr; 25(4):799-807. PubMed ID: 35994777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive value of partial
    Torre M; Wen PY; Iorgulescu JB
    Neurooncol Pract; 2023 Apr; 10(2):126-131. PubMed ID: 36970171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas.
    Haque W; Thong E; Andrabi S; Verma V; Brian Butler E; Teh BS
    J Clin Neurosci; 2021 Mar; 85():115-121. PubMed ID: 33581781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
    Tesileanu CMS; Sanson M; Wick W; Brandes AA; Clement PM; Erridge SC; Vogelbaum MA; Nowak AK; Baurain JF; Mason WP; Wheeler H; Chinot OL; Gill S; Griffin M; Rogers L; Taal W; Rudà R; Weller M; McBain C; van Linde ME; Aldape K; Jenkins RB; Kros JM; Wesseling P; von Deimling A; Hoogstrate Y; de Heer I; Atmodimedjo PN; Dubbink HJ; Brouwer RWW; van IJcken WFJ; Cheung KJ; Golfinopoulos V; Baumert BG; Gorlia T; French PJ; van den Bent MJ
    Clin Cancer Res; 2022 Jun; 28(12):2527-2535. PubMed ID: 35275197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
    Mohile NA; Messersmith H; Gatson NT; Hottinger AF; Lassman A; Morton J; Ney D; Nghiemphu PL; Olar A; Olson J; Perry J; Portnow J; Schiff D; Shannon A; Shih HA; Strowd R; van den Bent M; Ziu M; Blakeley J
    J Clin Oncol; 2022 Feb; 40(4):403-426. PubMed ID: 34898238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wildtype and -mutant lower grade gliomas.
    Kinslow CJ; Roy S; Iwamoto FM; Brown PD; DeStephano DM; Canoll PD; Qureshi SS; Gallito M; Sisti MB; Bruce JN; Horowitz DP; Kachnic LA; Neugut AI; Yu JB; Mehta MP; Cheng SK; Wang TJC
    Neuro Oncol; 2024 Jun; ():. PubMed ID: 38943513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex as a prognostic factor in adult-type diffuse gliomas: an integrated clinical and molecular analysis according to the 2021 WHO classification.
    Kim M; Kim S; Park YW; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Chang JH; Kim SH; Lee SK
    J Neurooncol; 2022 Sep; 159(3):695-703. PubMed ID: 35988090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical prognostic value of isocitrate dehydrogenase mutation, O-6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in glioma patients.
    Chen X; Yan Y; Zhou J; Huo L; Qian L; Zeng S; Li Z; Wei J; Xu Z; Gong Z
    Ann Transl Med; 2019 Oct; 7(20):541. PubMed ID: 31807523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II.
    Karschnia P; Teske N; Dorostkar MM; Siller S; Weller J; Baehring JM; Dietrich J; von Baumgarten L; Herms J; Tonn JC; Thon N
    Sci Rep; 2020 Nov; 10(1):19758. PubMed ID: 33184319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
    Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
    Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and predictive impact of MGMT promoter methylation status in high risk grade II glioma.
    Haque W; Teh C; Butler EB; Teh BS
    J Neurooncol; 2022 Mar; 157(1):137-146. PubMed ID: 35103907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
    Wang J; Huang Y; Zhao F; Chen J; He L; Liu Z; Pei Y; Wei Z; Li R; Ai P; Peng X
    J Neurooncol; 2022 Nov; 160(2):433-443. PubMed ID: 36357822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.